Sagimet Biosciences announces positive topline results from phase 2b trial of denifanstat
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
The receipt of this permission paves way for the launch of Andexanet alfa powder for solution for infusion 200 mg (Andexxa) in India
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients
This product has sales of about US$ 20 million in Europe
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Febuxostat Tablets (RLD Uloric) had estimated annual sales of US$ 27 million in the U.S. (IQVIA MAT November 2023)
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
Subscribe To Our Newsletter & Stay Updated